{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:09:05Z","timestamp":1792098545224,"version":"4.4.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"DOI":"10.3389\/fcell.2020.00865","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T04:21:16Z","timestamp":1598502076000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells"],"prefix":"10.3389","volume":"8","author":[{"given":"Xing-Duo","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiubin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Quan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Ning","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Xu","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1126\/science.aav7102","article-title":"Structural insight into substrate and inhibitor discrimination by human P-glycoprotein.","volume":"363","author":"Alam","year":"2019","journal-title":"Science"},{"key":"B2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/978-981-13-7647-4_12","article-title":"ABC transporter-mediated multidrug-resistant cancer","author":"Amawi","year":"2019","journal-title":"Drug Transporters in Drug Disposition, Effects and Toxicity. Advances in Experimental Medicine and Biology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113848","article-title":"Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2\/ABCB1 inhibitor.","volume":"175","author":"Cai","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.canlet.2015.10.010","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade.","volume":"370","author":"Chen","year":"2016","journal-title":"Cancer Lett."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00313","article-title":"Glesatinib, a c-MET\/SMO dual inhibitor, antagonizes P-glycoprotein mediated multidrug resistance in cancer cells.","volume":"9","author":"Cui","year":"","journal-title":"Front. Oncol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174095","article-title":"Chk1 inhibitor MK-8776 restores the sensitivity of chemotherapeutics in p-glycoprotein overexpressing cancer cells.","volume":"20","author":"Cui","year":"","journal-title":"Intern. J. Mol. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7905","DOI":"10.1158\/0008-5472.can-08-0499","article-title":"Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.","volume":"68","author":"Dai","year":"2008","journal-title":"Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s0923-2508(01)01194-9","article-title":"The ABC of ABCs: a phylogenetic and functional classification of ABC systems in living organisms.","volume":"152","author":"Dassa","year":"2001","journal-title":"Res. Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10911-009-9109-9","article-title":"ABC transporters, drug resistance, and cancer stem cells.","volume":"14","author":"Dean","year":"2009","journal-title":"J. Mamm. Gland Biol. Neoplasia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1021\/cr9000226","article-title":"ABC efflux pump-based resistance to chemotherapy drugs.","volume":"109","author":"Eckford","year":"2009","journal-title":"Chem. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.canlet.2018.01.021","article-title":"Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.","volume":"421","author":"Fan","year":"2018","journal-title":"Cancer Lett."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00955","article-title":"Erdafitinib antagonizes ABCB1-mediated multidrug resistance in cancer cells.","volume":"10","author":"Feng","year":"2020","journal-title":"Front. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737140.2020.1791705","article-title":"The current role of BTK inhibitors in the treatment of Waldenstrom\u2019s Macroglobulinemia.","author":"Gavriatopoulou","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1124\/dmd.108.022046","article-title":"Substrate-dependent breast cancer resistance protein (Bcrp1\/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.","volume":"37","author":"Giri","year":"2009","journal-title":"Drug Metab. Disposit."},{"key":"B15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters.","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.343","article-title":"Targeting Btk\/Etk of prostate cancer cells by a novel dual inhibitor.","volume":"5","author":"Guo","year":"2014","journal-title":"Cell Death Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1136\/annrheumdis-2013-204143","article-title":"Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants.","volume":"74","author":"Hartkamp","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2018.10.007","article-title":"Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1-and ABCG2-overexpressing cancer cells.","volume":"440","author":"Ji","year":"","journal-title":"Cancer Lett."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00514","article-title":"Midostaurin reverses ABCB1-mediated multidrug resistance, an in vitro study.","volume":"9","author":"Ji","year":"","journal-title":"Front. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"B21","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3109\/07388551.2015.1015957","article-title":"Molecular mechanisms of drug resistance and its reversal in cancer.","volume":"36","author":"Kartal-Yandim","year":"2016","journal-title":"Crit. Rev. Biotechnol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade.","volume":"18","author":"Kathawala","year":"","journal-title":"Drug Resist. Updates"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2638","article-title":"The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study.","volume":"6","author":"Kathawala","year":"","journal-title":"Oncotarget"},{"key":"B24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.lungcan.2005.03.035","article-title":"Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.","volume":"49","author":"Kitazaki","year":"2005","journal-title":"Lung Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/00029330-200606010-00006","article-title":"STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model.","volume":"119","author":"Lei","year":"2006","journal-title":"Chin. Med. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies.","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"B27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1152\/physiol.00046.2006","article-title":"Structure and function of ABC transporters.","volume":"22","author":"Linton","year":"2007","journal-title":"Physiology"},{"key":"B28","first-page":"2961","article-title":"Isolation of human KB cell lines resistant to epidermal growth factor-Pseudomonas exotoxin conjugates.","volume":"47","author":"Lyall","year":"1987","journal-title":"Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21114154","article-title":"Ibrutinib in gynecological malignancies and breast cancer: a systematic review.","volume":"21","author":"Metzler","year":"2020","journal-title":"Intern. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/art.38047","article-title":"Suppression of glomerulonephritis in lupus-prone NZB\u00d7 NZW mice by RN486, a selective inhibitor of Bruton\u2019s tyrosine kinase.","volume":"65","author":"Mina-Osorio","year":"2013","journal-title":"Arthrit. Rheum."},{"key":"B31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1600-065x.2008.00741.x","article-title":"Bruton\u2019s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol. Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13402-020-00541-5","article-title":"Aberrantly expressed Bruton\u2019s tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.","author":"Pikatan","year":"2020","journal-title":"Cell. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1574892811666161003112119","article-title":"Kinase inhibitor indole derivatives as anticancer agents: a patent review.","volume":"12","author":"Rathi","year":"2017","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.4103\/0019-509X.200658","article-title":"Cancer and cure: a critical analysis.","volume":"53","author":"Roy","year":"2016","journal-title":"Indian J. Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/s0169-409x(98)00085-4","article-title":"P-Glycoprotein, a gatekeeper in the blood-brain barrier.","volume":"36","author":"Schinkel","year":"1999","journal-title":"Adv. Drug Deliver. Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.addr.2012.09.027","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.","volume":"64","author":"Schinkel","year":"2012","journal-title":"Adv. Drug Deliver. Rev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1158\/1535-7163.mct-12-0302","article-title":"The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.","volume":"11","author":"Sen","year":"2012","journal-title":"Mol. Cancer Therap."},{"key":"B38","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies.","volume":"17","author":"Singh","year":"2018","journal-title":"Mol. Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.011.10329","article-title":"Multidrug resistance associated proteins in multidrug resistance.","volume":"31","author":"Sodani","year":"2012","journal-title":"Chin. J. Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1073\/pnas.94.5.2031","article-title":"Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.","volume":"94","author":"Sparreboom","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B41","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1134\/s0006297908050118","article-title":"Transport proteins of the ABC family and multidrug resistance of tumor cells.","volume":"73","author":"Stavrovskaya","year":"2008","journal-title":"Biochemistry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"570","DOI":"10.2174\/138920111795164048","article-title":"Revisiting the ABCs of multidrug resistance in cancer chemotherapy.","volume":"12","author":"Tiwari","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"B43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading Trott, Oleg; Olson, Arthur.","volume":"31","author":"Vina","year":"2010","journal-title":"J. Comput. Chem."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041387","article-title":"Overexpression of ABCB1 transporter confers resistance to mTOR inhibitor WYE-354 in cancer cells.","volume":"21","author":"Wang","year":"2020","journal-title":"Intern. J. Mol. Sci."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020466","article-title":"Venetoclax, a BCL-2 inhibitor, enhances the efficacy of chemotherapeutic agents in wild-type ABCG2-overexpression-mediated MDR cancer cells.","volume":"12","author":"Wang","year":"2020","journal-title":"Cancers"},{"key":"B46","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bcp.2014.06.006","article-title":"Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.","volume":"90","author":"Wang","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1021\/mp200261n","article-title":"The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy.","volume":"8","author":"Wu","year":"2011","journal-title":"Mol. Pharm."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010238","article-title":"The selective class IIa histone deacetylase inhibitor TMP195 resensitizes ABCB1-and ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs.","volume":"21","author":"Wu","year":"2020","journal-title":"Intern. J. Mol. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1124\/jpet.111.187740","article-title":"RN486, a selective Bruton\u2019s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.","volume":"341","author":"Xu","year":"2012","journal-title":"J. Pharmacol. Exper. Therap."},{"key":"B50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.canlet.2018.02.040","article-title":"Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: in vitro and in vivo.","volume":"424","author":"Zhang","year":"2018","journal-title":"Cancer Lett."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/1535-7163.mct-16-0511","article-title":"The BTK inhibitor ibrutinib (PCI-32765) overcomes paclitaxel resistance in ABCB1-and ABCC10-overexpressing cells and tumors.","volume":"16","author":"Zhang","year":"2017","journal-title":"Mol. Cancer Therap."},{"key":"B52","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1208\/s12248-015-9757-1","article-title":"Multidrug resistance proteins (MRPs) and cancer therapy.","volume":"17","author":"Zhang","year":"2015","journal-title":"AAPS J."},{"key":"B53","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.bmc.2014.10.043","article-title":"Discovery of novel Bruton\u2019s tyrosine kinase (BTK) inhibitors bearing a pyrrolo [2, 3-d] pyrimidine scaffold.","volume":"23","author":"Zhao","year":"","journal-title":"Bioorgan. Med. Chem."},{"key":"B54","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1016\/j.bmc.2015.06.023","article-title":"Pyrrolo [2, 3-b] pyridine derivatives as potent Bruton\u2019s tyrosine kinase inhibitors.","volume":"23","author":"Zhao","year":"","journal-title":"Bioorgan. Med. Chem."},{"key":"B55","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bmc.2014.11.006","article-title":"Design, synthesis and evaluation of novel 5-phenylpyridin-2 (1H)-one derivatives as potent reversible Bruton\u2019s tyrosine kinase inhibitors.","volume":"23","author":"Zhao","year":"","journal-title":"Bioorgan. Med. Chem."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005172","article-title":"Vandetanib (Zactima, ZD6474) antagonizes ABCC1-and ABCG2-mediated multidrug resistance by inhibition of their transport function.","volume":"4","author":"Zheng","year":"2009","journal-title":"PLoS One"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.00865\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T16:34:45Z","timestamp":1723480485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.00865\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":56,"alternative-id":["10.3389\/fcell.2020.00865"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2020.00865","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]},"article-number":"865"}}